GB Sciences, Inc.

Equities

GBLX

US3615441090

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 08:45:21 05/07/2024 pm IST			5-day change	1st Jan Change
0.0099 ^USD	+23.75%		+20.73%	+54.69%

02/07	GB Sciences, Inc Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson?s Formulation With Endopure Life Sciences	CI
12/02	GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

GB Sciences, Inc Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson?s Formulation With Endopure Life Sciences

July 02, 2024 at 06:30 pm IST

GB Sciences, Inc. has signed a letter of intent outlining terms for a licensing deal with Endopure Life Sciences, LLC. GB Sciences is licensing a suite of cannabinoid-based treatments for neurological disorders to Endopure Life Sciences. Aging populations have caused increased demand for treatments of neurological disorders, such as Parkinson's disease, Alzheimer's disease, dementia, multiple sclerosis, and epilepsy.

New products that address this important market are urgently needed.

Latest news about GB Sciences, Inc.

GB Sciences, Inc Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson?s Formulation With Endopure Life Sciences	02/07	CI
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02	CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	21/11	CI
GB Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	15/23/15	CI
GB Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	15/23/15	CI
GB Sciences, Inc. Auditor Raises 'Going Concern' Doubt	14/23/14	CI
Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of Lethbridge	11/23/11	CI
GB Sciences, Inc. announced a financing transaction	30/23/30	CI
GB Sciences, Inc. Announces Executive Changes	15/23/15	CI
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	04/23/04	CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	09/22/09	CI
Gb Sciences, Inc. Receives Positive Preclinical Results in an Interim Report from Its Study Using Preclinical Zebrafish Models of Stress At the National Research Council of Canada	24/22/24	CI
GB Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	12/22/12	CI
GB Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	01/22/01	CI
GB Sciences, Inc. Auditor Raises 'Going Concern' Doubt	30/22/30	CI
GB Sciences, Inc. announced a financing transaction	20/22/20	CI
Gb Sciences, Inc. Showcases Its Pharos™ Drug Discovery Platform At the 2Nd Alcor Drug Discovery Platform Summit	12/22/12	CI
GB Sciences, Inc. to Begin Dosage Study for its Novel Parkinson's Disease Formulations at the University of Lethbridge	12/22/12	CI
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations as Demonstrated in New Research Article	29/22/29	CI
GB Sciences, Inc. Announces Grant of U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis	01/22/01	CI
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	12/22/12	CI
An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. for $8 million.	11/22/11	CI
Gb Sciences Reports Positive Results from Study of its Potential Treatment for Cytokine Release Syndrome	06/21/06	CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	16/21/16	CI
GB Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation	14/21/14	CI

Chart GB Sciences, Inc.

Duration

Period

More charts

Company Profile

GB Sciences, Inc. is a biopharmaceutical research and development company. The Company develops disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its wholly owned subsidiary, GbS Global Biopharma, Inc. (GBSGB). The Company's primary focus is on preparing its lead program for the treatment of the motor symptoms of Parkinson's disease (PD) in a human clinical trial. Through GBSGB, the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB has a portfolio of intellectual property containing both plant-inspired formulations and its artificial intelligence (AI)-enabled drug discovery platform, as well as research contracts and various supplier arrangements. GBSGBs intellectual property covers a range of over 65 medical conditions, from which five drug development programs are in the preclinical stage of drug development.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GB SCIENCES, INC.	+54.69%	3.25M
MODERNA, INC.	+17.42%	44.44B
LONZA GROUP AG	+42.49%	40.03B
IQVIA HOLDINGS INC.	-10.75%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+30.26%	31.46B
CELLTRION, INC.	-9.23%	27.29B
ICON PUBLIC LIMITED COMPANY	+12.62%	26.29B
UNITED THERAPEUTICS CORPORATION	+42.66%	13.8B
MEDPACE HOLDINGS, INC.	+29.63%	12.46B
BIO-TECHNE CORPORATION	-7.47%	11.26B

Other Biotechnology & Medical Research